ESC 365 - Management of CV risk & type 2 diabetes mellitus (T2DM): implications of novel outcome trials.

ESC Premium Access

Management of CV risk & type 2 diabetes mellitus (T2DM): implications of novel outcome trials.

Session: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure (EBAC Accredited)

Topic: Drug therapy

Speaker: Professor J. Deanfield (London, GB)

Organised by Physicians' Academy for Cardiovascular Education, supported with an educational grant by Boehringer Ingelheim/Lilly

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor John Eric Deanfield

University College London, London (United Kingdom of Great Britain & Northern Ireland)

53 presentations

3 followers

4 more presentations in this session

Introduction - Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure.

Speaker: Doctor D. Fitchett (Toronto, CA)

SGLT2 inhibition in cardiology: what a cardiologist needs to know.

Speaker: Professor N. Sattar (Glasgow, GB)

Heart failure & diabetes: time for a more unified approach.

Speaker: Professor S. Anker (Berlin, DE)

Discussion - Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure.

Speaker: Doctor D. Fitchett (Toronto, CA) Professor J. Deanfield (London, GB)

Access the full session

Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure (EBAC Accredited)

Speakers: Professor J. Deanfield, Doctor D. Fitchett, Professor N. Sattar, Professor S. Anker, Doctor D. Fitchett...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources